The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery.
It is important when developing new vaccine systems to give proper attention to the question of delivery. In some cases the judicious choice of a delivery system can provide a greatly enhanced immune response and avoid the need to use a vaccine adjuvant. Delivery systems that have been developed originally for the administration of challenging drug can be used with success for vaccines. Polymer microspheres and lamellar particle based on the biodegradable materials polylactide and polylactide co-glycolide can be employed for the improved parenteral and mucosal administration of antigens. Likewise soluble biopolymers such as chitosan can be used for the improved nasal delivery of various antigens as well as DNA. Results from animal studies and recent clinical trials are provided.
Davis
Stanley S
SS
Institute of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham, NG7 2RD, UK. stanley.davis@nottingham.ac.uk
D020341:Absorbable Implants; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D007263:Infusions, Parenteral; D008863:Microspheres; D009092:Mucous Membrane; D011108:Polymers / Q000008:administration & dosage*; D012995:Solubility; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D011108:Polymers; D014612:Vaccines